Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawła II W Siedlcach Sp. z o.o.
- Address
- lock Available on a paid plan
Gynecologic Oncology Research
The Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawła II in Siedlce is actively investigating female urogenital diseases and related cancers. Current trials focus on advanced endometrial cancer, high‑grade serous ovarian cancer, and intermediate‑risk cervical cancer, aiming to improve adjuvant therapy, evaluate novel immunotherapy combinations, and test targeted maintenance strategies.
- Immunotherapy plus chemotherapy in high‑grade serous ovarian cancer
- Adjuvant pembrolizumab versus standard care in endometrial carcinoma
- Maintenance therapy with antibody‑drug conjugates after platinum response
- Neoadjuvant checkpoint inhibitor trials in cervical cancer
With 51 active studies and a team of nine investigators, the site contributes to the development of personalized treatments for women’s cancers across Poland.
Thoracic Oncology Studies
Trials at the centre also address neoplasms of the respiratory tract, particularly non‑small cell lung cancer (NSCLC) and extensive‑stage small cell lung cancer. Objectives include testing new checkpoint inhibitor combos, assessing maintenance regimens after chemoradiation, and comparing oral versus intravenous immunotherapies.
- Durvalumab plus oleclumab after concurrent chemoradiation for unresectable Stage III NSCLC
- Oral pembrolizumab formulation versus IV infusion in Stage IV NSCLC
- Combination of TLR7/8 agonist with pembrolizumab in locally advanced disease
- Novel ADC versus standard chemotherapy in extensive‑stage SCLC
The department’s thoracic oncology program leverages advanced imaging and biomarker analysis to accelerate the evaluation of innovative lung‑cancer therapies.
Melanoma and Cutaneous Cancer Research
The site’s portfolio includes studies on melanoma and other cutaneous malignancies, evaluating next‑generation antibody‑drug conjugates and combination immunotherapies to enhance response rates in advanced disease.
- Phase 3 comparison of a new ADC versus standard care in advanced melanoma
- Combination of ficerafusp alfa with pembrolizumab for melanoma
- Subcutaneous pembrolizumab with hyaluronidase versus IV administration in metastatic melanoma
- Safety run‑in of T‑cell engager therapies in melanoma patients
By integrating translational research with clinical evaluation, the centre aims to bring more effective skin‑cancer treatments to patients sooner.
Renal and Prostate Oncology Initiatives
Research on renal cell carcinoma and advanced prostate cancer is also prominent, with trials investigating hypoxia‑targeted agents, dual checkpoint blockade, and novel hormone‑resistance strategies.
- Belzutifan plus pembrolizumab versus placebo in RCC
- MK‑5684 versus enzalutamide in metastatic castration‑resistant prostate cancer
- Belzutifan and zanzalintinib versus cabozantinib in advanced kidney cancer
- I‑DXd versus docetaxel in metastatic castration‑resistant prostate cancer
The department’s multidisciplinary team supports these studies with state‑of‑the‑art imaging and molecular profiling, fostering progress in hard‑to‑treat urologic cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 112 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 111 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 20 by active trials.
- 1Merck Sharp & Dohme LLC10active
lock +19 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC21trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawła II W Siedlcach Sp. z o.o.
lock Showing 1 of 68 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 112 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 24 | Unknown | 2020-01-30 | 2026-01-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.